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Psoriasis is a common chronic-relapsing immune-mediated
pathology involving skin and joints of genetically predis-
posed individuals (Nickoloff and Nestle, 2004; Schon and
Boehncke, 2005), which potentially shares disease path-
ways with other chronic inflammatory diseases such as
rheumatoid arthritis and inflammatory bowel disease (Dav-
idson and Diamond, 2001). The pathogenesis of psoriasis is
dependent on activation and expansion of lesional and/or
circulating T cells culminating in a psoriasiform angiogenic
tissue reaction and epidermal hyperplasia (Boyman et al,
2004). Based on the analysis of infiltrating cell types, their
secreted products, and genetic signatures present in les-
ional skin, psoriasis is regarded as a type-1 tissue reaction
with a prominent role for T cell-derived interferon (IFN)-g
(Nestle et al, 1994; Lew et al, 2004). Given that environ-
mental factors such as mechanical stress and infections of
the skin represent a common trigger for disease relapses,
much effort has been devoted to understanding the link
between these unspecific stimuli and the pathogenic T cell
cascade leading to psoriasis. Recent evidence suggests
that type-1 IFN, a class of cytokines produced at early
stages of the innate immune response to pathogens, may
represent the missing link.
Type I IFN contain various family members (IFN-a
subtypes, -b, -e, -k, -o, -d, -t), the most abundant and
best-studied being IFN-a and -b. Although IFN-a/b can be
produced by virtually all cells of the human organism, plas-
macytoid dendritic cells (PDC), or ‘‘natural IFN-producing
cells’’ (NIPC) have the unique ability to produce up to 1000-
fold more IFN-a/b than any other cell type (Liu et al, 2001).
IFN-a/b share a heterodimeric receptor composed of IF-
NAR1 and IFNAR2. Ligand binding leads to receptor dime-
rization, auto-phosphorylation of Janus kinases (JAK),
recruitment and phosphorylation of signal transducer and
activator of transcription (STAT-1, STAT-2, STAT-3, STAT-4 in
some cell types), translocation of STAT homo- and het-
erodimers into the nucleus, and induced expression of a
large numbers of IFN-stimulated genes (ISG), including IFN
regulatory factor (IRF)-7, protein kinase (PKR) and myxovi-
rus-resistance (Mx) protein (Theofilopoulos et al, 2005). IRF-
7 is of special importance since it has been recently shown
to be the master regulator of the IFN-a/b mediated immune
response (Honda et al, 2005). Through the induction of ISG,
IFN-a/b exhibits a unique pleiotropy of biological effects
primarily aimed at a cellular state of antiviral defense, en-
compassing growth inhibition and immunomodulation (The-
ofilopoulos et al, 2005). Immunomodulatory effects include
upregulation of MHC class I, NK cell activation, and most
importantly activation of myeloid dendritic cells.
Although never convincingly demonstrated, a potential
involvement of IFN-a/b in the pathogenesis of psoriasis has
been previously suggested by the following observations: (i)
the induction of psoriasis after injection of recombinant
IFN-a (Funk et al, 1991), (ii) the presence of an activated
IFN-a/b signaling pathway in keratinocytes (van der Fits
et al, 2004), and (iii) the development of psoriasiform in-
flammation in IRF-2 knockout mice (Hida et al, 2000). A
functional role of IFN-a/b in the initiation of psoriasis has
been demonstrated very recently (Nestle et al, 2005). This
study showed that IFN-a was not elevated in fully estab-
lished psoriatic plaques but was transiently produced at
very early stages of psoriasis development (Boyman et al,
2004) and represented a key innate event leading to the
expansion of pathogenic T cells and to their activation into
effectors mediating the development of the psoriatic lesion
(Nestle et al, 2005).
In this issue, Wessel Eriksen et al provide a link between
IFN-a produced during psoriasis development and the Tcell
effector functions in psoriasis. IFN-a-induced signaling was
shown to be increased and prolonged in psoriatic T cells at
the level of STATactivation. Increased IFN-a signaling led to
increased STAT binding, IFN-g production, and inhibition of
Tcell growth. Interestingly, in addition to an increased STAT-
1 and STAT-2 activation, Wessel Eriksen et al (2005) also
show enhanced STAT-3 activation in psoriatic T cells which
complements recent data on the role of activated STAT-3 in
psoriatic keratinocytes (Sano et al, 2005). Wessel Eriksen
et al further demonstrate increased STAT-4 activation linking
IFN-a sensitivity of psoriatic T cells and generation of les-
ional Th-1 responses (Kaplan et al, 1996). The response to
IFN-a was specific since STAT responses to other cytokines
were not altered.
How can we integrate the findings of Wessel Eriksen et al
in the current view of the pathogenesis of psoriasis? An
integrated view is depicted in Fig 1. In uninvolved skin of
psoriatic patients there is an increased number of PDC
(Nestle et al, 2005). Innate activation of PDC to produce
IFN-a drives ‘‘quiescent’’ resident T cells in uninvolved
psoriatic skin into activated pathogenic effectors. This may
occur indirectly through the induction of myeloid DC acti-
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vation/maturation as suggested for SLE (Blanco et al, 2001).
In line with this scenario, myeloid dermal DC in psoriatic
skin are activated and have the ability to stimulate auto-
reactive Th-1 cells (Nestle et al, 1994). Additional indirect
effects of IFN-a on T cells include (i) the enhanced survival
and expansion of T cells through induction of IL-15 (Zhang
et al, 1998) and (ii) an increased cross-presentation of tissue
specific (auto-) antigens by lesional DC (Le Bon et al, 2003).
Wessel Eriksen et al suggest that IFN-amay also act directly
through activation of IFN-a sensitive lesional T cells. Fur-
thermore, increased STAT-4 activation in psoriatic T cells
links IFN-a sensitivity and generation of lesional Th-1 re-
sponses. These findings further strengthen the emerging
concept that IFN-a is an early innate master cytokine in
autoimmune diseases including psoriasis and raise several
important questions. What causes the increased IFN-a-
sensitivity in psoriatic T cells? Is there a genetic component
related to increased IFN-a sensitivity? Is the primary defect
in psoriasis rather an aberrant activation of the IFN-a path-
way as a consequence of the recruitment and the activation
of PDC in psoriatic skin? The molecular definition of ligands
activating lesional PDC as well as factors involved in the
generation and differentiation of lesional pathogenic T cells
may provide important clues to answer these questions.
How does IFN-a compare to TNF-a, a validated target for
psoriasis (Chaudhari et al, 2001; Boyman et al, 2004)? In
contrast to TNF-a, IFN-a production in psoriasis is a tran-
sient event occurring early during the psoriatic disease
process and is mainly confined to one cell type, dermal
PDC. It will be therefore of particular interest to test inhib-
itors of IFN-a and its signaling pathways as prophylactic
and therapeutic agents in psoriasis. Thus, we suggest a
spatial and temporal view of psoriasis development, in
which PDC-derived IFN-a represents an early and tightly
regulated upstream event preceding Th-1 mediated auto-
immune inflammation, induced by IFN-a sensitive auto-
reactive T cells.
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Figure 1
Interferon (IFN)-a links innate and adaptive immunity leading to the
development of psoriasis. A spatial and temporal view of psoriasis
development in which IFN-a production represents an early and tran-
sient event during the psoriatic disease process and is confined to
activated plasmacytoid dendritic cells (PDC) (innate immunity). Innate
activation of PDC may result from the release of skin-derived products
upon skin injury or infection. IFN-a stimulates the pathogenic T cell
cascade (adaptive immunity) indirectly by promoting the activation and
maturation of myeloid dendritic cells (MDC) or by direct stimulation of
IFN-a-sensitive pathogenic T cells, leading to Th1-mediated inflamma-
tion and the development of the psoriatic epidermal hyperproliferation.
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